Hormone Receptor-Positive Breast Cancer: How Long Does Endocrine Therapy Last? (2026 Update)

Hormone receptor-positive (ER/PR-positive) breast cancer is typically followed by endocrine therapy for 5 to 10 years after surgery, with the duration and choice of agents varying based on menopausal status and recurrence risk.

Key Takeaways

• If a tumor is hormone receptor-positive (ER, PR), the general course is to continue oral hormone therapy for 5 to 10 years after surgery.
• Different drugs are used depending on whether the patient is premenopausal or postmenopausal, and premenopausal patients may also receive injections to suppress ovarian function.
• In stage 4 (metastatic) disease, treatment often begins with a combination of endocrine therapy plus a CDK4/6 inhibitor.
• Because endocrine therapy can cause menopause-like symptoms and reduced bone density, bone density testing is typically done alongside treatment.
• Since this is an oral medication, treatment can be continued at a location outside Korea as long as a prescription and treatment plan are available.

Why Does Endocrine Therapy Sometimes Last 10 Years Instead of 5?

• Treatment duration is adjusted based on recurrence risk and cancer subtype. For hormone receptor-positive breast cancer, continuing endocrine therapy for 5 to 10 years after surgery is part of the standard approach.
• Hormone receptor-positive breast cancer has a characteristic tendency to recur late, sometimes even years later, which means the follow-up monitoring period tends to be longer than for other subtypes. For this reason, endocrine therapy itself is often extended as well.
• The exact duration is determined by the treating medical team based on a combination of factors including stage, lymph node involvement, age, and coexisting conditions, so it varies by individual.

How Does Treatment Differ Before and After Menopause?

• Different hormone therapy drugs are used depending on menopausal status, and premenopausal patients may also receive injections to suppress ovarian function alongside their medication.
• In metastatic (stage 4) disease, if the tumor is hormone receptor-positive, treatment often begins with a combination of endocrine therapy plus a CDK4/6 inhibitor. This combination is determined by subtype and stage rather than menopausal status alone.
• The specific drugs used, their sequencing, dosage, and administration intervals are decided based on a combination of menopausal status, genetic test results, and response to prior treatment.

What Side Effects Occur and How Are They Managed?

• Endocrine therapy can cause menopause-like symptoms such as hot flashes, joint stiffness, and vaginal dryness, and may also be accompanied by reduced bone density. Bone density testing is therefore managed alongside treatment over several years.
• Monitoring bone density and conducting gynecological exams together during the follow-up period is a common management approach.
• Since this is an oral medication, having a handoff document detailing the prescription, dosing plan, and testing schedule makes it easier for local medical staff to take over care if the patient relocates during treatment.

FAQ — Must Endocrine Therapy Be Received Only in Korea?

No, that is not the case. Since this is an oral medication, treatment can be continued elsewhere once a prescription and dosing plan are obtained. However, because this is long-term treatment spanning 5 to 10 years, it is recommended to obtain a handoff document outlining which drugs are used in what sequence and when specific tests should be performed, and to share this with the local medical team.

FAQ — Is Endocrine Therapy Alone Sufficient, or Is It Combined With Other Treatments?

This depends on stage and subtype. For early-stage (stage 1-2) breast cancer, it is common after surgery to combine chemotherapy, anti-HER2 targeted therapy, endocrine therapy, and radiation therapy depending on subtype and stage. For hormone receptor-positive early-stage breast cancer, genomic expression testing (multigene assays) may also be used to help determine whether chemotherapy is necessary. For stage 0 (carcinoma in situ), if the tumor is hormone receptor-positive, endocrine therapy alone may sometimes be considered sufficient.

Sources and Notes

• This article was written based on general breast cancer information from the National Cancer Registration Statistics 2019–2023 (Central Cancer Registry, National Cancer Center Korea), the National Cancer Information Center, and NCCN patient guidelines.
• This content is intended to provide general medical information, and actual diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment decisions should always be made in consultation with a medical professional.